Vivani Reports Positive Preclinical Data For NPM-139 Semaglutide Implant In Weight Management

(RTTNews) - Vivani Medical, Inc. (VANI) Wednesday announced encouraging data from the preclinical study of NPM-139 for chronic weight management in obese and overweight individuals.

NPM-139, a subdermal implant in development using the company's proprietary NanoPortal technology to deliver semaglutide, the active ingredient in Novo Nordisk's Ozempic/Wegovy.

Results from a preclinical study showed that treatment with NPM-139 resulted in nearly 20 percent weight loss from a single administration.

"Products containing semaglutide generated $25 billion in 2024 and demand for these products continues to soar. Since over half of these patients regularly miss doses as indicated by real-world medication adherence data, we believe that there is a tremendous opportunity for a more convenient delivery option that will eliminate missed doses and thereby improve real-world health outcomes," said Adam Mendelsohn, Vivani Medical's Chief Executive Officer.